SINGULAIR (R) as Complementary Therapy to Fixed Association Regimen (0476-363)

An Open Label, Observational Study to Assess The Efficacy, Safety and Tolerability of Added Singulair in Persistent Asthma Patients With or Without Allergic Rhinitis and Long Acting B-Agonist

The purpose of this study is to assess the treatment effect of montelukast 10mg on the primary endpoint of Asthma Control Questionnaire(ACQ), over a 8-week period, in persistent asthma patients with or without allergic rhinitis.

Inclusion Criteria:

• Patient is currently a nonsmoker and has been a nonsmoker for at least 1 year
• Patient with clinical evidence of mild/moderate asthma with or without allergic rhinitis

Exclusion Criteria:

• Patient has been treated in an emergency room for asthma within 4 weeks or has been hospitalized for asthma within 3 months prior to visit 1
• Patient with severe asthma, upper respiratory infection, sinusitis, infectious rhinitis, non-allergic rhinitis
• Patient has any active, acute, or chronic pulmonary disorder that is documented by history, physical examination